| P/E (FY) | — | Sales (TTM) | $288.1M |
| Earnings (TTM) | $22.3M | ROE | −111.05% |
| Net Margin | −43.53% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 114.98% |
Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes products for rare cardiopulmonary diseases in the United States. Its lead candidate, YUTREPIA, is an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and PH-ILD. It also offers Remodulin, a treprostinil injection, develops L606, a liposomal treprostinil formulation in Phase III trials, and provides PRINT technology for manufacturing uniform drug particles.
| Market Cap | $7.72B | Trading Days | 2008 |
| 52W High | 91.10 |
| 52W Low | 16.82 |
| % Off High | −4.70% |
| YTD | 151.73% | 1Y | 338.04% |
| 3Y | 1018.81% | 5Y | 3443.67% |
| Since incept. (ann.) | 29.30% |
Single Reportable 100%
| Ann. Volatility (1Y) | 67.18% | Ann. Volatility (3Y) | 64.46% |
| Sharpe (1Y) | 2.57 | Sharpe (3Y) | 1.61 |
| Max Drawdown (1Y) | −35.66% | Max Drawdown (3Y) | −46.80% |
| Beta (3Y, vs SPY) | 1.06 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.40B | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.84B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| PTCT | PTC THERAPEUTICS, INC. | $6.66B | 9.7 |
| NUVL | Nuvalent, Inc. | $9.01B | — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |